Effect of charged mutation on aggregation of a pentapeptide: Insights from molecular dynamics simulations

Aggregation of therapeutic monoclonal antibodies (mAbs) can negatively affect their chemistry, manufacturing, and control attributes and lead to undesirable immune responses in patients. Therefore, optimization of lead mAb drug candidates during discovery stages to mitigate aggregation is increasingly becoming an integral part of their developability assessments. The disruption of short sequence motifs called aggregation prone regions (APRs) found in amino acid sequences of mAb candidates can potentially mitigate their aggregation. In this work, we have performed molecular dynamics simulations to study the aggregation of an APR (VLVIY) found in lambda light chains of human antibodies and its single point mutant KLVIY. Eighteen different multicopy peptide simulation systems of VLVIY and KLVIY were constructed by varying their concentrations, temperatures, termini capping, and flanking gate-keeper regions. Within 20 ns of the simulation, peptide VLVIY formed an aggregate of 100 peptides at similar to 0.1 M concentration with a 60% reduction in solvent accessible surface area (SASA). Furthermore, analysis of the SASA change, peptide cluster distribution, and water residence time demonstrated how Val -> Lys mutation resists aggregation and improves solubility. Presence of Lys slows down aggregation kinetics via charge-charge repulsions and by raising the kinetic barrier to formation of large oligomers. However, the effect of the Val -> Lys mutation is dependent on sequence and structural contexts around the APR. This mutation also alters the solvation shell around the peptide by favoring solute-solvent interactions, thereby increasing its solubility. This work has provided a detailed mechanistic explanation of how APR disruption can mitigate aggregation in biotherapeutics and improve their developability.

Automated summary

The study investigated the aggregation of an APR (VLVIY) found in lambda light chains of human antibodies and its single point mutant KLVIY, showing that the Val->Lys mutation can resist aggregation and improve solubility by disrupting the APR. This mutation alters the solvation shell around the peptide, favoring solute-solvent interactions and increasing solubility.